AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca collaboration partner payables — Daiichi Sankyo (Enhertu & Datroway) non-current ($M) ($M)
Form 20-F Note 19 & Note 20 — Collaboration Payables, Supplier Finance & Contingent Consideration
Latest, FY2025
579
Period ended Dec 31, 2025
Change on a year earlier
+27.0%
456 in FY2024
History
2 years
Since FY2024
Sources
1
Form 20-F FY2025 Annual Report
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration partner payables — Daiichi Sankyo (Enhertu & Datroway) non-current ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 579 | +27.0% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 456 | – | Form 20-F FY2025 Annual Report ↗ |
Breakdown
What makes up collaboration partner payables — daiichi sankyo (enhertu & datroway) non-current ($m)
- Collaboration partner payables — Daiichi Sankyo current ($M)673 · FY2025
- Collaboration liability to Bond Avillion (Airsupra) non-current ($M)499 · FY2025
- Trade payables in Supplier Finance Arrangement ($M)100 · FY2025
- Suppliers enrolled in Supplier Finance Arrangement (suppliers)310 · FY2025
- Contingent consideration liability — non-current ($M)204 · FY2025
- Contingent consideration liability — current ($M)346 · FY2025
- Contingent consideration milestone & royalty cash paid ($M)1,164 · FY2025
Cite this data
StockData. (2026). AstraZeneca Collaboration partner payables — Daiichi Sankyo (Enhertu & Datroway) non-current ($M) ($M), annual FY2024–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/partner_payables_supply
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.